Study to compare drug availability in the bloodstream of two oral formulations of dexketoprofen in healthy volunteers under fasting conditions.

2025-524061-24-01 Protocol 1042/25;DEXO-0125/BE Human pharmacology (Phase I) - Bioequivalence study Ended

Start 13 Feb 2026 · End 4 Mar 2026 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 1042/25;DEXO-0125/BE

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 48
Countries 1
Sites 1

Bioequivalence clinical trial in healthy volunteers under fasting conditions.

Key facts

Sponsor
Faes Farma S.A.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Not possible to specify
Trial duration
13 Feb 2026 → 4 Mar 2026
Decision date (initial)
2026-02-06
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Bioequivalence clinical trial in healthy volunteers under fasting conditions.

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Faes Farma S.A.

Sponsor organisation
Faes Farma S.A.
Address
Autonomia Etorbidea 10
City
Leioa
Postcode
48940
Country
Spain

Scientific contact point

Organisation
Faes Farma S.A.
Contact name
Inmaculada Gilaberte Asín

Public contact point

Organisation
Faes Farma S.A.
Contact name
Inmaculada Gilaberte Asín

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ended 48 1
Rest of world 0

Investigational sites

Czechia

1 site · Ended
Quinta-Analytica s.r.o.
Clinical Unit, Prazska 1486/18c, Hostivar, Prague

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2026-02-13 2026-03-04 2026-02-13 2026-02-21

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-01-27 Czechia Acceptable
2026-02-06
2026-02-06